Published in Genes Dev on February 15, 2006
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol (2007) 2.66
Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet (2006) 1.66
Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets. Cell Cycle (2011) 1.46
Balancing the decision of cell proliferation and cell fate. Cell Cycle (2009) 1.36
JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div (2010) 1.29
E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases. EMBO J (2009) 1.28
DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol Cell Biol (2011) 1.03
Retinoblastoma protein regulation by the COP9 signalosome. Mol Biol Cell (2007) 1.02
COP9-associated CSN5 regulates exosomal protein deubiquitination and sorting. Am J Pathol (2009) 1.01
CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res (2008) 1.01
A combinatorial mechanism for determining the specificity of E2F activation and repression. Oncogene (2009) 0.94
Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B. J Biol Chem (2009) 0.94
E2f2 induces cone photoreceptor apoptosis independent of E2f1 and E2f3. Cell Death Differ (2013) 0.92
Stable form of JAB1 enhances proliferation and maintenance of hematopoietic progenitors. J Biol Chem (2008) 0.90
Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. Cancer Biol Ther (2014) 0.89
CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner. Sci Rep (2013) 0.88
Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. J Biol Chem (2011) 0.86
Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures. Nucleic Acids Res (2015) 0.78
To live or let die - complexity within the E2F1 pathway. Mol Cell Oncol (2015) 0.78
A highly conserved regulatory element controls hematopoietic expression of GATA-2 in zebrafish. BMC Dev Biol (2007) 0.78
Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress. J Biol Chem (2015) 0.77
E2F1-Mediated Induction of NFYB Attenuates Apoptosis via Joint Regulation of a Pro-Survival Transcriptional Program. PLoS One (2015) 0.76
Expression level is a key determinant of E2F1-mediated cell fate. Cell Death Differ (2017) 0.75
Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast. Genetics (1996) 24.62
The regulation of E2F by pRB-family proteins. Genes Dev (1998) 12.77
Effects of an Rb mutation in the mouse. Nature (1992) 11.06
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature (1992) 8.16
Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A (1997) 5.83
p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A (1994) 5.49
E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell (1996) 5.26
Tumor surveillance via the ARF-p53 pathway. Genes Dev (1998) 5.11
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A (1994) 5.11
The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell (2003) 4.97
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J (1999) 4.69
Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ (1998) 4.38
The E2F1-3 transcription factors are essential for cellular proliferation. Nature (2001) 4.37
Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol (1994) 4.36
Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature (1999) 4.35
COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell (2003) 4.25
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (2000) 3.83
E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol (1995) 3.55
E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev (1998) 3.48
Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev (2001) 3.41
The E2F family: specific functions and overlapping interests. EMBO J (2004) 3.33
E2f3 is critical for normal cellular proliferation. Genes Dev (2000) 3.26
The COP9 signalosome. Annu Rev Cell Dev Biol (2003) 3.25
Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol (2003) 3.12
Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell (1998) 3.05
Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet (2000) 3.03
Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 3.00
Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol (2001) 2.96
Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. Nat Genet (1998) 2.53
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim Biophys Acta (2002) 2.47
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J (2001) 2.41
A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature (1996) 2.33
The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J Cell Biol (2001) 2.26
E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev (2001) 2.16
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature (2000) 2.10
Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol Cell (1998) 2.02
The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol (1995) 1.97
E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ (1998) 1.96
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol (2003) 1.84
Arabidopsis homologs of a c-Jun coactivator are present both in monomeric form and in the COP9 complex, and their abundance is differentially affected by the pleiotropic cop/det/fus mutations. Plant Cell (1998) 1.81
Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E. Nat Genet (1999) 1.76
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Deletion of the Cul1 gene in mice causes arrest in early embryogenesis and accumulation of cyclin E. Curr Biol (1999) 1.63
Direct repression of the Mcl-1 promoter by E2F1. Oncogene (2002) 1.60
Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J Biol Chem (2004) 1.58
Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol (2004) 1.57
E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep (2005) 1.51
Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ (2002) 1.51
Disruption of the COP9 signalosome Csn2 subunit in mice causes deficient cell proliferation, accumulation of p53 and cyclin E, and early embryonic death. Mol Cell Biol (2003) 1.46
JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep (2001) 1.45
COP9 signalosome subunits 4 and 5 regulate multiple pleiotropic pathways in Drosophila melanogaster. Development (2002) 1.43
E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol (2002) 1.30
COP9 signalosome subunit 3 is essential for maintenance of cell proliferation in the mouse embryonic epiblast. Mol Cell Biol (2003) 1.26
The Arabidopsis CSN5A and CSN5B subunits are present in distinct COP9 signalosome complexes, and mutations in their JAMM domains exhibit differential dominant negative effects on development. Plant Cell (2004) 1.10
Regulation of E2F1-dependent gene transcription and apoptosis by the ETS-related transcription factor GABPgamma1. Mol Cell Biol (2002) 0.93
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol (2006) 1.57
Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A (2002) 1.51
The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem (2003) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev (2004) 1.42
Balancing the decision of cell proliferation and cell fate. Cell Cycle (2009) 1.36
Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35
Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A (2005) 1.34
Origin of bistability underlying mammalian cell cycle entry. Mol Syst Biol (2011) 1.32
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26
Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26
Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res (2003) 1.26
Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle (2011) 1.25
Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res (2010) 1.24
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol (2010) 1.20
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res (2009) 1.19
Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res (2008) 1.19
An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer. BMC Genomics (2008) 1.14
Genomic strategies for personalized cancer therapy. Hum Mol Genet (2007) 1.14
Retracted Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood (2005) 1.12
Utilization of genomic signatures to identify phenotype-specific drugs. PLoS One (2009) 1.12
Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A (2005) 1.09
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles. PLoS One (2010) 1.07
Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Mol Ther (2002) 1.06
Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent Prog Horm Res (2003) 1.04
Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell (2011) 1.03
Stochastic E2F activation and reconciliation of phenomenological cell-cycle models. PLoS Biol (2010) 1.03
Temporal control of cell cycle gene expression mediated by E2F transcription factors. Cell Cycle (2005) 1.03
Patterns of cell signaling pathway activation that characterize mammary development. Development (2008) 1.02
Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res (2010) 1.01
Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A (2007) 1.01
Phylogenetic simulation of promoter evolution: estimation and modeling of binding site turnover events and assessment of their impact on alignment tools. Genome Biol (2007) 0.99
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res (2009) 0.98
Utilization of genomic signatures to direct use of primary chemotherapy. Curr Opin Genet Dev (2008) 0.96
Gene expression phenotypes of oncogenic signaling pathways. Cell Cycle (2003) 0.95
SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics (2011) 0.94
Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med (2011) 0.94
Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression. J Biol Chem (2013) 0.93
The Rb-related p130 protein controls telomere lengthening through an interaction with a Rad50-interacting protein, RINT-1. Mol Cell (2006) 0.93
Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med (Berl) (2010) 0.92
Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors. BMC Med Genomics (2011) 0.91
A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet (2009) 0.90
Multimodal regulation of E2F1 gene expression by progestins. Mol Cell Biol (2010) 0.90
Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med (2010) 0.87
Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. N Engl J Med (2011) 0.87
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. Cancer Res (2013) 0.87
Evolving strategies for targeted cancer therapy--past, present, and future. J Natl Cancer Inst (2004) 0.86
Toward the individualization of lung cancer therapy. Cancer (2008) 0.85
A mechanism of COOH-terminal binding protein-mediated repression. Mol Cancer Res (2005) 0.83
Use of gene expression and pathway signatures to characterize the complexity of human melanoma. Am J Pathol (2011) 0.81
A methodology for utilization of predictive genomic signatures in FFPE samples. BMC Med Genomics (2011) 0.80
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2011) 0.78
Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2011) 0.78
DIG--a system for gene annotation and functional discovery. Bioinformatics (2005) 0.77
E2F6 associates with BRG1 in transcriptional regulation. PLoS One (2012) 0.77
Peripheral blood signatures of lead exposure. PLoS One (2011) 0.75
Using noisy gene expression mediated by engineered adenovirus to probe signaling dynamics in mammalian cells. Methods Enzymol (2011) 0.75
An overview of genomic data analysis. Surgery (2004) 0.75